We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Environmental Exposure and Neurological Diseases Questionnaire

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02916966
Recruitment Status : Suspended (Research Quality & Safety Review)
First Posted : September 28, 2016
Last Update Posted : September 6, 2022
Sponsor:
Collaborator:
The Cleveland Clinic
Information provided by (Responsible Party):
Elijah W. Stommel, Dartmouth-Hitchcock Medical Center

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The proposed research is particularly relevant to the National ALS Registry and public environmental health issues because it addresses the potential environmental causes of sporadic ALS. The research will develop an ALS surveillance program in Ohio that can be compared with the national and State-Metro Surveillance Programs of the National ALS Registry, and novel methodologies to determine the role of the cyanobacterial toxin, BMAA (beta-methylamino-L-alanine), and other environmental toxins/toxicants as risk factors for ALS. This work will advance the mission of the Centers for Disease Control Agency for Toxic Substances and Disease Registry (CDC ATSDR) National ALS Registry by offering data on ALS cases in Ohio that address public health concerns over the effects of chronic exposure to cyanobacterial blooms in Lake Erie.

Condition or disease Intervention/treatment
Amyotrophic Lateral Sclerosis Other: Patient Registry

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 2000 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Case-control and Population Questionnaire Studying Environmental Risk Factors and Neurological Diseases
Actual Study Start Date : October 2016
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
ALS Patients in Case-Control
ALS patients enrolled by Cleveland Clinic Foundation (CCF)
 Other: Patient Registry
Patient Registry
Non-neurodegenerative patients in case control
Non-neurodegenerative patients enrolled by CCF
 Other: Patient Registry
Patient Registry
Non-neurodegeneration population in population control
Non-neurodegenerative general population enrolled by ABS mailing system from DHMC
 Other: Patient Registry
Patient Registry
ALS Patients in State of OH
ALS registry of all cases in Ohio
 Other: Patient Registry
Patient Registry


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Questionnaire for Environmental Exposures, Toxins, and Neurological Disease [ Time Frame: 1 year ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
  1. ALS patients in case-control at CCF
  2. Non-neurodegenerative patients in case control at CCF
  3. Non-neurodegenerative general population in Ohio
  4. ALS patient registry in Ohio
Criteria

Inclusion Criteria:

  • ALS
  • Non-neurodegenerative controls
  • Can willingly give consent
  • Over 18 years of age

Exclusion Criteria:

  • Cannot give consent
  • Under 18 years of age
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02916966


Locations
Layout table for location information
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
The Cleveland Clinic
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Elijah W. Stommel, Professor of Neurology, Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier: NCT02916966    
Other Study ID Numbers: D06019
First Posted: September 28, 2016    Key Record Dates
Last Update Posted: September 6, 2022
Last Verified: September 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Nervous System Diseases
Neurodegenerative Diseases
Neuromuscular Diseases
 Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases